I. Junk Science Clinical Trials as the Basis for FDA Licensure of Hepatitis B Vaccines in the U.S. 

The Advisory Committee on Immunization Practices (ACIP) will discuss hepatitis B vaccines at their meeting on December 4 and 5. In this article I will lay out the case for removing hepatitis B vaccines from the CDC childhood schedule altogether.

As the Informed Consent Action Network has demonstrated, the hepatitis B vaccines Recombivax and Engerix — injected into the vast majority of American children at birth, one month, and six months of age — never should have been licensed by the FDA in the first place. 

The clinical trials for Recombivax and Engerix:

• did not include a proper saline placebo control group; 

• were too small to detect uncommon adverse events; and

• were too short to detect the majority of harms (the Recombivax trials monitored safety for just five days, the Engerix trials monitored solicited adverse events for just four days).

________________________________________________________________________________

II. Hepatitis B Vaccines Are Associated with Autism 

The real world data that are available on the safety of hepatitis B vaccines are horrifying. When autism rates in the US exploded in the 1990s, the CDC looked into the possible role of vaccines. They assigned one of their senior scientists, Thomas Verstraeten, at the Epidemic Intelligence Service, to do the analysis. At the time, hepatitis B vaccines had mercury (thimerosal) in them. Dr. Verstraeten found that children in the highest exposure group had an 11.35x increased relative risk of autism.